Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Current immuno-oncology relies on PD-1/PD-L1 antibody inhibitors.
• Targeting other PD-1 pathway steps is an underexplored area.
• Small molecule PD-1 inhibitors are needed.

Purpose of the Study:

• To identify novel small molecule inhibitors of PD-1 signaling.
• To investigate methylene blue (MB) as a potential PD-1 inhibitor.

Main Methods:

• Investigated MB's effect on CD8+ cytotoxic T lymphocyte (CTL) function.
• Examined MB's mechanism of action by analyzing PD-1 and SHP2 interaction.
• Assessed MB's efficacy in mouse models of lung cancer and on human T cells.

Main Results:

• MB significantly enhances CTL cytotoxicity, proliferation, activation, and cytokine secretion.
• MB blocks the interaction between phosphorylated PD-1 and SHP2.
• MB reduces tumor size in PD-L1 expressing lung cancer models and modulates human T cell function.

Conclusions:

• Methylene blue is a potent inhibitor of PD-1 signaling.
• MB represents a novel strategy for developing small molecule PD-1 inhibitors.
• This finding expands therapeutic options in immuno-oncology.